Jason Coloma, Ph.D., serves as Chief Executive Officer of Maze Therapeutics Inc., a clinical-stage precision medicine company pioneering therapies for kidney diseases. With over two decades of leadership in biotechnology, Dr. Coloma drives Maze's mission to transform patient care through its proprietary Maze Compass platform, which integrates human genetics, functional genomics, and machine learning to uncover disease drivers and develop targeted treatments. Under his guidance, Maze has advanced its lead program, MZE001, into Phase 2 clinical trials for APOL1-mediated kidney disease (AMKD), positioning the company as a leader in addressing unmet needs in rare and common kidney disorders. Dr. Coloma's distinguished career includes pivotal roles at Genentech, a member of the Roche Group, where he most recently served as Vice President of Early-Stage Oncology and Head of the gRED Innovative Medicines Accelerator. In these positions, he spearheaded the discovery and development of multiple oncology programs, forging strategic partnerships, and accelerating innovative therapies from concept to clinic. Earlier, he held leadership roles in business development and diagnostics at Roche and Tercica, contributing to landmark deals and product launches that advanced personalized medicine. A biophysicist by training, Dr. Coloma earned his Ph.D. from the University of California, Berkeley, and completed postdoctoral work at Genentech. His expertise in structural biology, drug discovery, and translational research has earned him recognition as a visionary leader, with a track record of building high-performing teams and delivering breakthrough innovations in complex therapeutic areas. At Maze, he continues to champion data-driven approaches to unlock new biology and deliver life-changing medicines for patients worldwide.